

First granted ICOone® patent in India

Iconovo AB (publ) has been granted its first patent in India on the inhalation platform ICOone®. Iconovo has previously granted ICOone® patents in Europe (EPO) and have several patents pending in USA, India, China and Japan.

ICOone® is Iconovo's platform for simple and cost-efficient delivery of vaccines and biomolecules to the lung. Since ICOone® delivers a dry powder, there is no need for expensive and complicated cold storage. Inhaling the drug eliminates the use of disposable syringes and no hazardous waste with blood contaminated syringes is generated.

A good example of ICOone® use is the cooperation with Monash University. In this project Oxytocin is administered to women during birth to prevent heavy bleeding, Postpartum Hemorrhage (PPH). Oxytocin is today typically delivered as an injection and requires cold storage, which can be very challenging in regions with less developed infrastructure. PPH is globally the most common cause of maternal mortality with over 60 000 fatalities annually. India represents a significant part of all PPH cases.

"A patent in India is extremely important for us since it is a large potential market for which ICOone® is particularly well suited. A cheap, simple and safe way to supply vaccines to a large population is of great interest to many of our potential customers, not the least in India", says Dr. Orest Lastow, CTO and founder at Iconovo.

About ICOone®

ICOone® is a unique, patented dry powder inhaler for single use. The smart design generates an ultra-low manufacturing cost combined with simple and discreet use. It is particularly suitable for short-term treatment and as-needed use as it provides an unsurpassed low treatment cost and price point for treatments with a low number of doses. The simple design also enables patients and caregivers to learn how to handle the inhalers with minimal training. ICOone® can deliver large inhalation doses that are well protected against moisture, an important factor for many biomolecules.

<https://iconovo.se/products/icoone/>

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Attachments

[First granted ICOone® patent in India](#)